9 months of delamanid, linezolid, levofloxacin, and pyrazinamide versus conventional therapy for treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-END): a multicentre, randomised, open-label phase 2/3 non-inferiority trial in South Korea
- 문서 유형
- 연구출판물 · 학술지 논문
- 등재
- Nature IndexSCIEScopus
- 저널 순위
- JCR Q1Scopus Q1
- 저널
- LANCET400(10362) · pp.1522 · 2022
- 피인용
- Web of Science 61Scopus 67
- FWCI (Scopus)
- 7.11
- JCR IF
- JCR 2021 202.731
- ISSN
- 0140-6736
저자
- 목정하제1저자Pusan Natl Univ Hosp, Dept Internal Med, Div Pulmonol Allergy & Crit Care Med, Busan, South Korea
- Lee, MyungsunInt TB Res Ctr, Div Clin Res, Seoul, South Korea
- Kim, Deog KyeomSeoul Natl Univ, Dept Internal Med, Div Pulm & Crit Care Med, Seoul Metropolitan Govt,Boramae Med Ctr, Seoul, South Korea
- Kim, Ju SangCatholic Univ Korea, Coll Med, Dept Internal Med, Div Pulmonol & Crit Care Med,Incheon St Marys Hos, Seoul, South Korea
- Jhun, Byung WooSungkyunkwan Univ, Samsung Med Ctr, Dept Med, Div Pulm & Crit Care Med,Sch Med, Seoul, South Korea
- Jo, Kyung-WookUniv Ulsan, Asan Med Ctr, Dept Internal Med, Div Pulmonol & Crit Care Med,Coll Med, Seoul, South Korea
- 전두수Pusan Natl Univ, Dept Internal Med, Yangsan Hosp, Yangsan, South Korea
- Lee, TaehoonUniv Ulsan, Ulsan Univ Hosp, Dept Internal Med, Div Pulm & Crit Care Med,Coll Med, Ulsan, South Korea
- Lee, Ji YeonNatl Med Ctr, Dept Internal Med, Div Pulm & Crit Care Med, Seoul, South Korea
- Park, Jae SeukDankook Univ Hosp, Dept Internal Med, Div Pulm & Crit Care Med, Cheonan, South Korea
- Lee, Seung HeonKorea Univ, Dept Pulmonol, Ansan Hosp, Ansan, South Korea
- Kang, Young AeYonsei Univ, Severance Hosp, Dept Internal Med, Div Pulm & Crit Care Med,Coll Med, Seoul, South Korea
- Lee, Jung-KyuSeoul Natl Univ, Dept Internal Med, Div Pulm & Crit Care Med, Seoul Metropolitan Govt,Boramae Med Ctr, Seoul, South Korea
- Kwak, NakwonSeoul Natl Univ Hosp, Dept Internal Med, Div Pulm & Crit Care Med, Seoul, South Korea
- Ahn, Joong HyunCatholic Univ Korea, Coll Med, Dept Internal Med, Div Pulmonol & Crit Care Med,Incheon St Marys Hos, Seoul, South Korea
- Shim, Tae SunUniv Ulsan, Asan Med Ctr, Dept Internal Med, Div Pulmonol & Crit Care Med,Coll Med, Seoul, South Korea
- Kim, Song YeeYonsei Univ, Severance Hosp, Dept Internal Med, Div Pulm & Crit Care Med,Coll Med, Seoul, South Korea
- Kim, SeungmoKorean Inst TB, Dept Lab Med, Cheongju, South Korea
- Kim, KyungjongKorean Inst TB, Dept R&D, Cheongju, South Korea
- Seok, Kwang-HyukKorean Inst TB, Dept Lab Med, Cheongju, South Korea
- Yoon, SoyeongInt TB Res Ctr, Div Clin Res, Seoul, South Korea
- Kim, Young RanInt TB Res Ctr, Div Clin Res, Seoul, South Korea
- Kim, JisuSeoul Natl Univ Hosp, Med Res Collaborating Ctr, Seoul, South Korea
- Yim, DahaeSeoul Natl Univ Hosp, Med Res Collaborating Ctr, Seoul, South Korea
- Hahn, SeokyungSeoul Natl Univ, Dept Human Syst Med, Coll Med, Seoul, South Korea
- Cho, Sang NaeInt TB Res Ctr, Div Clin Res, Seoul, South Korea
- Yim, Jae-Joon교신저자Seoul Natl Univ, Dept Internal Med, Coll Med, Seoul, South Korea
초록
© 2022 Elsevier LtdBackground: With the introduction of new anti-tuberculosis drugs, all-oral regimens with shorter treatment durations for multidrug-resistant tuberculosis have been anticipated. We aimed to investigate whether a new all-oral regimen was non-inferior to the conventional regimen including second-line anti-tuberculosis drugs for 20–24 months in the treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis. Methods: In this multicentre, randomised, open-label phase 2/3 non-inferiority trial, we enrolled men and women aged 19–85 years with multidrug-resistant tuberculosis confirmed by phenotypic or genotypic drug susceptibility tests or rifampicin-resistant tuberculosis by genotypic tests at 12 participating hospitals throughout South Korea. Participants with fluoroquinolone-resistant multidrug-resistant tuberculosis were excluded. Participants were randomly assigned (1:1) to two groups using a block randomisation, stratified by the presence of diabetes and cavitation on baseline chest radiographs. The investigational group received delamanid, linezolid, levofloxacin, and pyrazinamide for 9 months, and the control group received a conventional 20–24-month regimen, according to the 2014 WHO guidelines. The primary outcome was the treatment success rate at 24 months after treatment initiation in the modified intention-to-treat population and the per-protocol population. Participants who were “cured” and “treatment completed” were defined as treatment success following the 2014 WHO guidelines. Non-inferiority was confirmed if the lower limit of a 97·5% one-sided CI of the difference between the groups was greater than −10%. Safety data were collected for 24 months in participants who received a predefined regimen at least once. This study is registered with ClinicalTrials.gov, NCT02619994. Findings: Between March 4, 2016, and Sept 14, 2019, 214 participants were enrolled, 168 (78·5%) of whom were included in the modified intention-to-treat population. At 24 months after treatment initiation, 60 (70·6%) of 85 participants in the control group had treatment success, as did 54 (75·0%) of 72 participants in the shorter-regimen group (between-group difference 4·4% [97·5% one-sided CI –9·5% to ∞]), satisfying the predefined non-inferiority margin. No difference in safety outcomes was identified between the control group and the shorter-regimen group. Interpretation: 9-month treatment with oral delamanid, linezolid, levofloxacin, and pyrazinamide could represent a new treatment option for participants with fluoroquinolone-sensitive multidrug-resistant tuberculosis. Funding: Korea Disease Control and Prevention Agency, South Korea
키워드
식별자
- Scopus EID
- 2-s2.0-85140470877
- WoS UID
- 000923383000025



로그인
연구물 목록으로